To include your compound in the COVID-19 Resource Center, submit it here.

Sarepta acquires Myonexus, reports LGMD trial results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed efficacy data from a Phase I/II trial of one of the candidates, MYO-101, in a cohort of patients

Read the full 530 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers